![]() ![]() Many Afib patients are now choosing Xarelto or Eliquis over Coumadin.īarnes explains the pros and cons of these medications. The FDA approved Xarelto and Eliquis nearly 10 years ago to prevent stroke and systemic blood clots in patients with Afib and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. “Choosing between medications such as Coumadin, Xarelto or Eliquis depends on the individual patient’s needs and preferences.”Īll blood-thinning medicines slow the formation of blood clots, preventing complications such as valve obstruction and blood clots that travel to the brain and cause stroke.īut, says Barnes, “there are advantages and disadvantages to each.” , many patients wonder: Does newer mean better? Not always, he says. Īccording to University of Michigan Frankel Cardiovascular Center cardiologist Geoffrey Barnes, M.D., M.Sc. LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher. However, newer blood thinners, or anticoagulants, to treat Afib have been introduced in the last decade, including Xarelto (rivaroxaban) and Eliquis (apixaban). According to the American Heart Association, at least 2.7 million Americans are living with Afib.Īfib has long been treated with the blood thinner Coumadin, also known as warfarin, which the FDA approved in 1954. ![]() Atrial fibrillation, also known as Afib, is a quivering or irregular heartbeat ( arrhythmia ) that can lead to blood clots, stroke, heart failure and other heart-related complications. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |